Skip to content

Survey of family satisfaction with continuous sedation provided by a palliative care team

Survey of family satisfaction with palliative care team intervention in continuous sedation for pain relief

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
JPRN
Registry ID
JPRN-jRCT1060240107
Enrollment
20
Registered
2025-01-17
Start date
2025-01-17
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Terminally ill patients

Interventions

None listed

Sponsors

Ueno Yusuke
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: The target audience is family members of patients who have received sedation, which is defined as "the administration of sedatives to relieve treatment-resistant pain."

Exclusion criteria

Exclusion criteria: Sedation is not recommended if opioids or antipsychotics cause decreased consciousness. Nighttime administration of sleeping pills for treatment-resistant non-painful insomnia is also not recommended.

Design outcomes

Primary

MeasureTime frame
The questionnaire used for evaluation was the 2nd edition of the Scale for Assessment of the Structure and Process of Palliative Care by Bereaved Families.

Secondary

MeasureTime frame
The diagnosis, age, sex, physical findings, test results (blood tests, imaging tests, etc.), nursing records, percentage of patients who underwent sedation for pain relief, percentage of patients who underwent PCT intervention, duration of sedation, target symptoms, drugs used, and the decision-making process of patients and their families for patients who underwent sedation that corresponds to "administration of sedatives for the purpose of alleviating treatment-resistant pain."

Contacts

Public ContactYusuke Ueno

Kagawa University Hospital

yusukeueno912@yahoo.co.jp+81-87-891-2167

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026